Investors are looking more keenly at Midwest healthcare startups – cash invested has doubled this year over last, according to a recent report.
Some $777 million was invested across 139 companies for just the first half of 2014, according to the BioEnterprise Midwest Healthcare Venture Investment Report. By comparison, $758 million across 213 companies was raised for the totality of 2013.
The medical device sector won the lion’s share of dollars, receiving $342 million, or 44 percent of the funding. Biopharma received 31 percent, or $240 million, and healthcare IT rounded out the bottom with $196 million, or 25 percent. The region’s venture funding, state by state, can be seen below:
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
A number of large medical device deals in Minnesota help it clinch the spot as venture darling: The state had four deals that were more than $20 million apiece – Holaira raised $42 million for its lung device that treats COPD; Inspire Medical raised $40 million for its sleep apnea therapy; NxThera had an oversubscribed Series C for its endourology device and Tendyne raised $25 million for its device that treats leaky heart valves.
The Midwest’s largest deal is also the most recent – Missouri’s Essence Group Holdings last week raised $71 million for its population health management tool.
Cancer drugmaker ProNai Therapeutics raised the largest venture round in Michigan’s history with its $60 million Series D to further develop its DNA interference technology.
Other big deals include Indiana-based Orthopediatrics attracting $39 million, and Ohio’s Aerpio Therapeutics raising $22 million.